FAS and FAS-Ligand Promoter Polymorphisms in Hepatitis B Virus Infection

Authors Information
Article Notes and Dates
To Cite : Mohammadi A, Tajik N, Shah-Hosseini A, Alavian S M, Sharifi Z, et al. FAS and FAS-Ligand Promoter Polymorphisms in Hepatitis B Virus Infection, Hepat Mon. 2015 ;15(10):e26490. doi: 10.5812/hepatmon.26490.
Copyright: Copyright © 2015, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Wei Y, Neuveut C, Tiollais P, Buendia MA. Molecular biology of the hepatitis B virus and role of the X gene. Pathol Biol (Paris). 2010; 58(4): 267-72[DOI][PubMed]
  • 2. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris). 2010; 58(4): 258-66[DOI][PubMed]
  • 3. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol. 2005; 79(15): 9369-80[DOI][PubMed]
  • 4. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30(12): 2212-9[DOI][PubMed]
  • 5. Lavanchy D. Viral hepatitis: global goals for vaccination. J Clin Virol. 2012; 55(4): 296-302[DOI][PubMed]
  • 6. Bertoletti A, Maini M, Williams R. Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control. Antiviral Res. 2003; 60(2): 61-6[PubMed]
  • 7. Ichiki Y, He XS, Shimoda S, Ishibashi H, Keeffe EB, Rossaro L, et al. T cell immunity in hepatitis B and hepatitis C virus infection: implications for autoimmunity. Autoimmun Rev. 2005; 4(2): 82-95[DOI][PubMed]
  • 8. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science. 1999; 284(5415): 825-9[PubMed]
  • 9. Chen Y, Wei H, Gao B, Hu Z, Zheng S, Tian Z. Activation and function of hepatic NK cells in hepatitis B infection: an underinvestigated innate immune response. J Viral Hepat. 2005; 12(1): 38-45[DOI][PubMed]
  • 10. Notas G, Kisseleva T, Brenner D. NK and NKT cells in liver injury and fibrosis. Clin Immunol. 2009; 130(1): 16-26[DOI][PubMed]
  • 11. Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol. 2009; 86(3): 513-28[DOI][PubMed]
  • 12. Gao B, Radaeva S. Natural killer and natural killer T cells in liver fibrosis. Biochim Biophys Acta. 2013; 1832(7): 1061-9[DOI][PubMed]
  • 13. Jung M, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis. 2002; 2(1): 43-50[DOI]
  • 14. Yang PL, Althage A, Chung J, Maier H, Wieland S, Isogawa M, et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A. 2010; 107(2): 798-802[DOI][PubMed]
  • 15. Oshimi Y, Oda S, Honda Y, Nagata S, Miyazaki S. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol. 1996; 157(7): 2909-15[PubMed]
  • 16. Hayashi N, Mita E. Involvement of Fas system-mediated apoptosis in pathogenesis of viral hepatitis. J Viral Hepat. 1999; 6(5): 357-65[PubMed]
  • 17. Zou Y, Chen T, Han M, Wang H, Yan W, Song G, et al. Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure. J Immunol. 2010; 184(1): 466-75[DOI][PubMed]
  • 18. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut. 2005; 54(7): 1024-33[DOI][PubMed]
  • 19. Oksuz M, Akkiz H, Isiksal YF, Saydaogluc G, Serin M, Kayaselcuk F, et al. Expression of Fas antigen in liver tissue of patients with chronic hepatitis B and C. Eur J Gastroenterol Hepatol. 2004; 16(3): 341-5[PubMed]
  • 20. Behrmann I, Walczak H, Krammer PH. Structure of the human APO-1 gene. Eur J Immunol. 1994; 24(12): 3057-62[DOI][PubMed]
  • 21. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S. Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol. 1994; 6(10): 1567-74[PubMed]
  • 22. Huang QR, Morris D, Manolios N. Identification and characterisation of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 1997; 34(8-9): 577-82[DOI]
  • 23. Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003; 170(1): 132-8[PubMed]
  • 24. Rivero M, Crespo J, Fabrega E, Casafont F, Mayorga M, Gomez-Fleitas M, et al. Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus. J Viral Hepat. 2002; 9(2): 107-13[PubMed]
  • 25. Lee JY, Chae DW, Kim SM, Nam ES, Jang MK, Lee JH, et al. Expression of FasL and perforin/granzyme B mRNA in chronic hepatitis B virus infection. J Viral Hepat. 2004; 11(2): 130-5[PubMed]
  • 26. Bortolami M, Kotsafti A, Cardin R, Farinati F. Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease. J Viral Hepat. 2008; 15(7): 515-22[DOI][PubMed]
  • 27. Bai J, Odin JA. Apoptosis and the liver: relation to autoimmunity and related conditions. Autoimmun Rev. 2003; 2(1): 36-42[DOI]
  • 28. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3): 1215[PubMed]
  • 29. Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004; 96(13): 1030-6[PubMed]
  • 30. Hiraide A, Imazeki F, Yokosuka O, Kanda T, Kojima H, Fukai K, et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol. 2005; 100(6): 1322-9[DOI][PubMed]
  • 31. Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens. 2007; 69(3): 227-35[DOI][PubMed]
  • 32. Marin LA, Muro M, Moya-Quiles MR, Miras M, Minguela A, Bermejo J, et al. Study of Fas (CD95) and FasL (CD178) polymorphisms in liver transplant recipients. Tissue Antigens. 2006; 67(2): 117-26[DOI][PubMed]
  • 33. Aguilar-Reina J, Ruiz-Ferrer M, Pizarro MA, Antinolo G. The -670A > G polymorphism in the promoter region of the FAS gene is associated with necrosis in periportal areas in patients with chronic hepatitis C. J Viral Hepat. 2005; 12(6): 568-73[DOI][PubMed]
  • 34. Zamani AG, Barlas IO, Durakbasi-Dursun G, Ural O, Erdal E, Yildirim MS. Evaluation of death pathway genes FAS and FASL polymorphisms in chronic HBV infection. Int J Immunogenet. 2013; 40(6): 482-7[DOI][PubMed]
  • 35. Jung YJ, Kim YJ, Kim LH, Lee SO, Park BL, Shin HD, et al. Putative association of Fas and FasL gene polymorphisms with clinical outcomes of hepatitis B virus infection. Intervirology. 2007; 50(5): 369-76[DOI][PubMed]
  • 36. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med. 1997; 3(4): 409-13[PubMed]
  • 37. Balkow S, Kersten A, Tran TT, Stehle T, Grosse P, Museteanu C, et al. Concerted action of the FasL/Fas and perforin/granzyme A and B pathways is mandatory for the development of early viral hepatitis but not for recovery from viral infection. J Virol. 2001; 75(18): 8781-91[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check